NERV News and Press, Minerva Neurosciences Inc From 06/28/23

BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 s...

2023-05-19 17:34:30 ET Summary NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispute resolution process to its advantage. No adv...

2023-05-15 11:26:05 ET Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Conference Call May 15, 2023, 8:30 AM ET Company Participants Geoff Race - President Dr. Remy Luthringer - Executive Chairman and CEO Fred Ahlholm - Senior Vice President and CFO Con...

2023-05-15 07:38:20 ET Minerva Neurosciences press release ( NASDAQ: NERV ): Q1 GAAP EPS of -$1.31. Cash, cash equivalents, and restricted cash as of March 31, 2023 were approximately $36.1 million, compared to $36.2 million as of December 31, 2022. For further detai...

BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first qua...

2023-05-10 09:06:14 ET The U.S. Food and Drug Administration (FDA) accepted to review Minerva Neurosciences' ( NASDAQ: NERV ) application seeking approval of roluperidone to treat negative symptoms in patients with schizophrenia. Earlier in May, the FDA filed the com...

BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial...

2023-05-01 13:03:11 ET Gainers: Sentage Holdings ( SNTG ) +268% . Quhuo Limited ( QH ) +160% . Midwest Holding ( MDWT ) +87% . Baosheng Media Group Holdings Limited ( BAOS ) +76% . Meihua International Medical Technologies ( MHUA ) ...

Minerva Neurosciences, Inc. (NASDAQ: NERV) is one of today's top gainers. The company's shares are currently up 58.66% on the day to $4.39. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the tr...

2023-05-01 10:03:58 ET Gainers: Nano-X Imaging ( NNOX ) +53% . Meihua International Medical Technologies ( MHUA ) +34% .  Minerva Neurosciences ( NERV ) +27% . Apollomics ( APLM ) +24% . Ascendis Pharma ( ASND ) +19% . ...